Meta-Analysis of Bioprosthetic Valve Thrombosis after Transcatheter Aortic Valve Implantation.
暂无分享,去创建一个
S. Achenbach | M. Joner | S. Windecker | S. Stortecky | T. Pilgrim | M. Marwan | S. Cassese | E. Xhepa | O. Husser | N. Mayr | C. Pellegrini | T. Rheude | F. Ammon
[1] Jeroen J. Bax,et al. Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Valves: PARTNER 3 Cardiac Computed Tomography Substudy. , 2020, Journal of the American College of Cardiology.
[2] M. Mack,et al. Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement. , 2020, The New England journal of medicine.
[3] C. Hengstenberg,et al. Hemodynamic structural valve deterioration following transcatheter aortic valve implantation with latest-generation balloon-expandable valves. , 2020, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[4] C. Terkelsen,et al. Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement. , 2019, The New England journal of medicine.
[5] J. Tijssen,et al. A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. , 2019, The New England journal of medicine.
[6] F. Nietlispach,et al. Incidence, predictors and cerebrovascular consequences of leaflet thrombosis after transcatheter aortic valve implantation: a systematic review and meta-analysis. , 2019, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[7] J. Leipsic,et al. Transcatheter Aortic‐Valve Replacement with a Balloon‐Expandable Valve in Low‐Risk Patients , 2019, The New England journal of medicine.
[8] Andrew S. Mugglin,et al. Transcatheter Aortic‐Valve Replacement with a Self‐Expanding Valve in Low‐Risk Patients , 2019, The New England journal of medicine.
[9] M. Mack,et al. Clinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Aortic Valves by Four-Dimensional Computed Tomography. , 2018, The Annals of thoracic surgery.
[10] F. Neumann,et al. Medium-Term Follow-Up of Early Leaflet Thrombosis After Transcatheter Aortic Valve Replacement. , 2018, JACC. Cardiovascular interventions.
[11] L. Räber,et al. Transcatheter aortic valve thrombosis: incidence, clinical presentation and long-term outcomes , 2018, European heart journal cardiovascular Imaging.
[12] H. Rashid,et al. Bioprosthetic aortic valve leaflet thrombosis detected by multidetector computed tomography is associated with adverse cerebrovascular events: a meta-analysis of observational studies. , 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[13] S Achenbach,et al. Leaflet thrombosis following transcatheter aortic valve implantation. , 2017, Journal of cardiovascular computed tomography.
[14] V. Letocart,et al. Could anticoagulation avoid bioprosthesis subclinical thrombosis in patients undergoing transcatheter aortic valve replacement? , 2018, Archives of cardiovascular diseases.
[15] B. Prendergast,et al. Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Societ , 2017, European heart journal.
[16] Wen Cheng,et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study , 2017, The Lancet.
[17] Jeroen J. Bax,et al. Transcatheter aortic valve thrombosis: the relation between hypo-attenuated leaflet thickening, abnormal valve haemodynamics, and stroke , 2017, European heart journal.
[18] G. Richardt,et al. Clinical Bioprosthetic Heart Valve Thrombosis After Transcatheter Aortic Valve Replacement: Incidence, Characteristics, and Treatment Outcomes. , 2017, JACC. Cardiovascular interventions.
[19] O. Alfieri,et al. Single-Antiplatelet Therapy in Patients with Contraindication to Dual-Antiplatelet Therapy After Transcatheter Aortic Valve Implantation. , 2017, The American journal of cardiology.
[20] G. Richardt,et al. Comparison of dual antiplatelet therapy versus oral anticoagulation following transcatheter aortic valve replacement: A retrospective single-center registry analysis. , 2017, Cardiology journal.
[21] A. Ducci,et al. Transcatheter aortic valves produce unphysiological flows which may contribute to thromboembolic events: An in-vitro study , 2016, Journal of biomechanics.
[22] C. Terkelsen,et al. Transcatheter Aortic Valve Thrombosis: Incidence, Predisposing Factors, and Clinical Implications. , 2016, Journal of the American College of Cardiology.
[23] M. Hernán,et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions , 2016, British Medical Journal.
[24] J. Leipsic,et al. Early hypo-attenuated leaflet thickening in balloon-expandable transcatheter aortic heart valves. , 2016, European heart journal.
[25] M. Jinzaki,et al. Incidence, Predictors, and Mid-Term Outcomes of Possible Leaflet Thrombosis After TAVR. , 2016, JACC. Cardiovascular imaging.
[26] Deepak L. Bhatt,et al. Possible Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves. , 2015, The New England journal of medicine.
[27] J. Leipsic,et al. Early Aortic Transcatheter Heart Valve Thrombosis: Diagnostic Value of Contrast-Enhanced Multidetector Computed Tomography , 2015, Circulation. Cardiovascular interventions.
[28] O. Alfieri,et al. Treatment and Clinical Outcomes of Transcatheter Heart Valve Thrombosis , 2015, Circulation. Cardiovascular interventions.
[29] Robert L Grant,et al. Converting an odds ratio to a range of plausible relative risks for better communication of research findings , 2014, BMJ : British Medical Journal.
[30] J. Sterne,et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.